Bone Biologics Corporation BBLG

BBLG Company Overview

Bone Biologics Corporation is a U.S.-based biotechnology and medical device company focused on developing orthobiologic products for spine fusion and other musculoskeletal applications. The company operates within the regenerative medicine and orthopedic biologics industries, with its core strategy centered on advancing bone regeneration technologies intended to improve outcomes in spinal fusion procedures. Its primary product development efforts have focused on therapies derived from recombinant human proteins and growth-factor-based approaches designed to stimulate bone formation.

The company’s principal technology platform has been associated with the development of NELL-1-based bone regeneration therapeutics, which originated from research conducted at the University of California, Los Angeles (UCLA). Bone Biologics has positioned itself as a development-stage enterprise seeking to address limitations associated with traditional bone grafting methods and existing biologic fusion products. According to public filings and company disclosures, its evolution has involved licensing intellectual property, pursuing preclinical and clinical development pathways, and seeking strategic financing to support commercialization efforts.